v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash $ 12,670,143 $ 5,106,872
Prepaid insurance 56,388 26,682
Other prepaid expenses 72,488 44,825
Note receivable Nomad Transportable Power Systems 6,500,000
Total current assets 19,299,019 5,178,379
LiGHT proton therapy system equipment 6,607,419 6,582,560
Operating lease right-of-use assets 742,427 972,682
Total assets 26,648,865 12,733,621
Current liabilities:    
Accounts payable and accrued expenses, including $29,258 and $125,959 to related parties 327,890 436,482
Research and development contract liabilities 231,342 232,138
Operating lease liabilities, current 940,775 595,418
Series B Convertible Preferred Stock 8% cumulative dividend payable 69,073
Total current liabilities 1,500,007 1,333,111
Operating lease liabilities, long-term 161,019 438,959
Total liabilities 1,661,026 1,772,070
Commitments and Contingencies
Stockholders’ Equity:    
Common stock, $0.0001 par value authorized – 100,000,000 shares; issued and outstanding – 15,417,444 and 8,790,102 shares at June 30, 2026 and December 31, 2025, respectively 1,541 879
Additional paid-in capital 86,097,966 66,008,824
Accumulated deficit (62,188,147) (58,077,213)
Total Lixte Biotechnology stockholders’ equity 23,911,360 9,664,059
Non-controlling interest 1,076,479 1,297,492
Total stockholders’ equity 24,987,839 10,961,551
Total liabilities and stockholders’ equity 26,648,865 12,733,621
Series B Convertible Preferred Stock [Member]    
Stockholders’ Equity:    
Series B Convertible Preferred Stock, $0.7146 per share stated value – issued and outstanding – none at June 30, 2026 and 2,423,130 as of December 31, 2025 $ 1,731,569